FDA OKs First ‘Extended’ Adjuvant Treatment for HER2 Breast Cancer

The FDA has approved a new drug for patients with early-stage HER2-positive breast cancer who have completed trastuzumab and want “extended” adjuvant therapy.
FDA Approvals …read more